Login with Linked

Follow us on

Link Linkedin Youtube

Posluma

Posluma is a PSMA-targeted PET imaging agent used in prostate cancer. It helps doctors detect and locate primary and metastatic prostate tumors more accurately using a novel radiohybrid compound.

Molecule Details :

  • Molecule Name :

    Flotufolastat F 18

  • Innovator :

    BLUE EARTH DIAGNOSTICS LTD

  • Approval Date :

    25-May-23

  • NCE-1 Date :

    25-May-27

  • NCE Date :

    25-May-28

  • Dosage Form :

    Intravenous Solution

  • Strength :

    25ML (8-158mCi/ML)

  • Therapeutic Category :

    Diagnostic Agents

  • Revenue ($M) :

    NA

Year-wise Projected Sales ($M) :

  • 2025 :

    NA

  • 2026 :

    NA

  • 2027 :

    NA

  • 2028 :

    NA

  • 2029 :

    NA

  • 2030 :

    NA

  • 2031 :

    NA
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.
Request a Quote

Why Choose Spring Bio Solution?

Supported 1000+ Clinical Trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO Services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions 


Schedule a Call With Us
Login with Linked

Follow us on

Linkedin Youtube Link

Login NCE Grid

Register NCE Grid

Are you sure want to logout from NCE Grid?

Not Now
Logout
Need your comparator insight?